The incorporation of monoclonal antibodies to first line treatment of Multiple Myeloma improves survival rates Published on 07/09/2021 Autologous transplantation continues to be part of the standard treatment for newly diagnosed patients with no comorbidities, as well as the combination of chemotherapy with the anti-CD38 monoclonal antibody